Vital Connect, Aventyn Launch Wearable Biosensor Platform for Mobile Patient Monitoring
(PRWEB) December 12, 2013 -- mHealthSummit 2013 – Washington DC – Dec 9, 2013 – Vital Connect and Aventyn Inc. announced a collaboration today to commercialize the combination of the Vitalbeat mobile remote monitoring platform and Vital Connect HealthPatch MD biosensor for hospitals and other healthcare providers. Vitalbeat is designed to help clinicians better manage chronic disease patient populations, including congestive heart failure (CHF) patients, and prevent avoidable readmissions.
Vital Connect is an industry pioneer of the HealthPatch MD wearable biosensor technology for use in medical applications. The HealthPatch MD biosensor is capable of capturing clinical-grade biometric measurements in a continuous, configurable and non-obtrusive manner using a small yet powerful patch worn on the chest. Encapsulated within the HealthPatch MD are cutting-edge sensor and chip technologies which combined with Vital Connect’s proprietary algorithms, enable the device to provide clinical-grade measurements of eight core health metrics: single lead ECG, heart rate, heart rate variability, respiratory rate, skin temperature, body posture, steps and fall detection/severity. Additionally, the HealthPatch MD can provide intelligent health measurements. Processing thousands of data points per minute, Vital Connect’s sophisticated SensorFusion algorithms analyze multiple biometrics to generate measurements that are more meaningful and accurate than any individual biometric alone. These measurements can include stress, energy expenditure (caloric burn), sleep quality, and contextual heart rate, among other health predictors.
Vitalbeat from Aventyn is a clinical evidence-based, simple, and cost-effective remote patient monitoring and integrated chronic disease management system. With Vitalbeat, cardiac centers, primary care physicians, skilled nursing facilities, home health service providers, can remotely monitor patients’ vital signs, health metrics, symptoms and medication adherence securely using traditional and mobile computing devices including Ultrabooks, smartphones, gateways and tablet devices. Clinically proven long-term disease management programs are enabled by Vitalbeat for CHF and co-morbidities such as diabetes, chronic obstructive pulmonary disease (COPD), hypertension, sleep apnea, chronic kidney disease (CKD), amongst other chronic conditions. Patients and healthcare providers manage health metrics, diet, physical activity, and medication compliance by configurable alerts and reminders based on personalized thresholds, goals and clinical guidelines. Vitalbeat patient electronic health record (EHR) data integrates with BlueButton and Continuity of Care Document (CCD) compliant EHR’s, along with social media platforms, to provide care continuity and improved quality of life with better outcomes.
“Vital Connect is pleased to be partnering with Aventyn due to their significant experience in remote patient monitoring in North America, Europe and Asia,” said Vital Connect CEO, Nersi Nazari. “The collaboration between Aventyn and Vital Connect will be a driving force to advance the deployment of mobile patient monitoring technologies in hospitals and other care facilities. Not only will the Vitalbeat platform and HealthPatch MD biosensor improve quality of care, it will also help hospitals reduce overhead by decreasing the number of readmissions after a procedure because doctors will be able to detect complications and take action much sooner.”
“We are delighted to collaborate with Vital Connect, a clear innovator in wearable clinical grade biosensors that improve personalized health monitoring,” said Navin Govind, founder and CEO at Aventyn. “The combination of the HealthPatch MD biosensor with Vitalbeat will enable our clinicians and innovative hospital partners to deliver revolutionary standard-of-care and cost-effective treatment that improve outcomes to meet the global need for heart failure care. The Vital Connect medical technology leadership and Aventyn mobile disease monitoring solution infrastructure with smart analytics can now scale to deliver affordable care to chronic patients and treat millions of discharge populations regardless of location.”
Vitalbeat with HealthPatch MD is now available for commercial deployment in select regions. Providers, payers, research centers and service providers can contact Aventyn to participate in upcoming clinical studies, trials and pilots for commercial deployment. Contact Puja Chandler: [email protected] or by phone +1 (231) RX4-BEAT
About Aventyn, Inc.
Aventyn is an award winning health technology company delivering innovative, standards based secure core to cloud connected clinical information processing solutions. The company’s CLIP®Care EMR solution with CareLock™ health information security and integrated wireless bio-sensor capability enable continuity of care anytime, anywhere and anyplace. Vitalbeat Integrated Chronic Disease Management patient personalized solutions are tailored for bedside, home and remote monitoring. Aventyn offers bundled and per patient per month subscription solutions with strategic provider and payer partners. Aventyn AB, Aventyn UK Ltd and Aventyn India Pvt Ltd are wholly owned subsidiaries of Aventyn Inc., USA.
About Vital Connect
Vital Connect is a Silicon Valley-based company founded in 2011 with the goal to develop the newest generation of technologies that help address some of the most challenging healthcare issues in the world today. Vital Connect’s extensive expertise enables the company to create wireless, wearable biosensors that are small, powerful, and capable of capturing clinical-grade biometric measurements in a continuous, configurable and non-obtrusive manner. Through various partnerships, Vital Connect solutions will be available for use in hospitals, research facilities, doctor’s offices, care facilities and homes. For more information, visit: http://www.vitalconnect.com.
Puja Chandler, Aventyn, Inc., http://www.aventyn.com, +1 (231) 794-2328, [email protected]
Share this article